Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Adrenocortical Carcinoma: early-phase trial registry
3 of 10 indexed Adrenocortical Carcinoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,724 of 28,707 conditions by registered trial count.
10 US clinical trials · 3 currently recruiting · #1,724 of 28,707 conditions by registered trial count
Adrenocortical Carcinoma: 10 US clinical trials tracked, 3 recruiting.
Adrenocortical Carcinoma is the subject of 10 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 2 of these trials.
Enrollment posture brief
Registry condition adrenocortical-carcinoma
OPEN 3 | RECR 30% | LATE 0 | EARLY 7 | RANK #1724 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Alcohol; Harmful Use (30% recruiting · 10 trials)
Adrenocortical Carcinoma lists 3 open slots (30% of 10 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Adrenocortical Carcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Adrenocortical Carcinoma is recruiting below its size-band peers.
3 of 10 indexed trials (30%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Adrenocortical Carcinoma research.
Memorial Sloan Kettering Cancer Center accounts for 2 of 10 trials (20%). 9 distinct sponsors appear on at least one study for this condition label.
-
Most Adrenocortical Carcinoma trials plan to enrol fewer than 100 people.
Median target enrolment is 68 among the 9 trials that report a genuine target (sentinel values excluded). 6 of those (66.7%) plan for fewer than 100 participants.
-
Adrenocortical Carcinoma research is mostly interventional.
7 interventional and 3 observational studies make up this index (70% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
10 total, page 1 of 1
Familial Investigations of Childhood Cancer Predisposition
St. Jude Children's Research Hospital
NCT03050268
Surgery and Heated Intraperitoneal Chemotherapy for Adrenocortical Carcinoma
Columbia University
NCT03127774
Study of Radiotherapy and Pembrolizumab in People With Adrenocortical Carcinoma
Memorial Sloan Kettering Cancer Center
NCT06066333
Optimal Methods of Disease Progression and Survival Analysis in Children and Adults Patients With Adrenocortical Cancer (ACC)
National Cancer Institute (NCI)
NCT04358107
Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors
Dana-Farber Cancer Institute
NCT03333616
Single Agent Pembrolizumab in Subjects With Advanced Adrenocortical Carcinoma
Memorial Sloan Kettering Cancer Center
NCT02673333
Natural History Study of Infants With Adrenal Masses Found on Prenatal and/or Neonatal Imaging
Children's Oncology Group
NCT00445718
A Dose Finding Study of TKM-080301 Infusion in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC) Patients
Arbutus Biopharma Corporation
NCT01262235
Phase 1 Study of ATR-101 in Subjects With Advanced Adrenocortical Carcinoma
Millendo Therapeutics
NCT01898715
Combination Chemotherapy With Suramin Plus Doxorubicin in Treating Patients With Advanced Solid Tumors
Mayo Clinic
NCT00003038
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 4 |
Top Sponsors
Named interventions
Most-linked intervention names on Adrenocortical Carcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Adrenocortical Carcinoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Adrenocortical Carcinoma page
10 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 Adrenocortical Carcinoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Memorial Sloan Kettering Cancer Center sponsors the most Adrenocortical Carcinoma trials on record, review their full trial history before evaluating a specific study. See Memorial Sloan Kettering Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Adrenocortical Carcinoma condition card totals 10 registered trials; most-linked intervention Pembrolizumab; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.